Mauro Valente

Dr. Mauro Valente

Nephrology, Dialysis and Renal Transplantation, Azienda Ospedaliero Universitaria delle Marche, Ancona, Marche, Italy
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 November 2020 in Blood Purification
Verified
Journal Article
Open access
PDF file
TRTeresa Rampino
Teresa Rampino
Marilena GregoriniMarilena Gregorini
Marilena Gregorini
LPLuciano Perotti
Luciano Perotti
FFFiorenza Ferrari
Fiorenza Ferrari
EPEleonora Francesca Pattonieri
Eleonora Francesca Pattonieri
MBMirko Belliato
Mirko Belliato
We report a preliminary experience of adjuvant therapy with Hemoperfusion (HP) in patients with Severe Acute Respiratory Syndrome-CoronaVirus 2 (SARS-CoV2) pneumonia. Currently, there are no approved treatments for CoronaVirus Disease 19 (COVID-19); however, therapeutic strategies based on the preclinical evidence include supportive measures, such as oxygen supplementation, antiviral, and anticoagulant agents. Despite these treatments, 10% of patients worsen and develop severe acute respiratory distress syndrome (ARDS). Since the pathogenic mechanism of ARDS is an uncontrolled inflammatory state, we speculate that removing inflammation effectors from blood may contrast tissue injury and improve clinical outcome. In a scenario of dramatic medical emergency, we conducted an observational study on 9 consecutive patients hospitalized in COVID Intensive Care Unit, where 5 of 9 consecutive patients were treated with HP, due to the emergency overload made it impossible to deliver blood purification in the other 4 patients. COVID-19 was diagnosed through the identification of virus sequences by reverse transcription-PCR on respiratory specimens. All patients had severe pneumonia requiring continuous positive airway pressure. HP was started in all patients 6–7 days after hospital admission. The treated patients (T) received 2 consecutive sessions of HP using CytoSorb cartridge. Our results show a better clinical course of T compared to control patients (C), in fact all T except 1 survived, and only 2 of them were intubated, while all C required intubation and died. Lymphocytopenia worsened in C but not in T. C-reactive protein decreased in both patients, but to a greater extent in T. IL-6, IL-8, and TNF-α decreased after HP, IL-10 did not change. Respiratory function remained stable and did not worsen in T compared to C. The limited sample size and observational study design preclude a sound statement about the potential effectiveness of HP in COVID-19 patients, but our experience suggests a potential therapeutic role of adjuvant CytoSorb HP in the early course of CO­VID-19 pneumonia. A randomized clinical trial is ongoing.

1 January 2019 in Transplantation Proceedings
Verified
Journal Article
Closed access
MGM. Gregorini
M. Gregorini
VMV. Martinelli
V. Martinelli
ETE. Ticozzelli
E. Ticozzelli
MCM. Canevari
M. Canevari
GFG. Fasoli
G. Fasoli
TRT. Rampino
T. Rampino

5 December 2017
Verified
Journal Article
Closed access
MGMarilena Gregorini
Marilena Gregorini
EPEleonora Francesca Pattonieri
Eleonora Francesca Pattonieri
GFGianluca Fasoli
Gianluca Fasoli
MVMauro Valente
Mauro Valente
EPEdoardo La Porta
Edoardo La Porta
TRTeresa Rampino
Teresa Rampino

14 June 2023 in Nephrology Dialysis Transplantation
Verified
Journal Article
Open access
PDF file
MVMauro Valente
Mauro Valente
FOFrancesca Orecchioni
Francesca Orecchioni
FBFabiana Brigante
Fabiana Brigante
MMMaria Ilaria Moretti
Maria Ilaria Moretti
MDMarcello D'ERrico
Marcello D'ERrico
ARAndrea Ranghino
Andrea Ranghino
Ralstonia (RB) and Burkholderia (BB) species are environmental Gram-negative bacilli responsible for several nosocomial infections in immunocompromised or frail patients. RB and BB may contaminate medical devices because of their ability to survive in a biofilm and with low nutrient requests. Reports of infection outbreaks due to RB and BB are very few and only in sporadic cases, the source of contamination was identified. We describe here: i) how we managed an outbreak of bacteremia caused by RB and BB occurred in our dialysis unit, ii) what we have done to identify the source of infection and iii) the countermeasures we adopted to reduce the risk of new events. From 7 to 16 April 2021, 6 out of 39 (15.4%) hemodialyzed (HD) patients with a long-term indwelling central venous catheter (CVC) developed symptoms related to infection. Blood cultures revealed the presence of RB and BB. Thus, a prompt check of the blood cultures of all HD patients with CVC was performed. Blood samples were incubated in an automated microbial detection system (VIRTUO BIOMERIEUX) and subsequently, blood positive samples were inoculated in Chocolate and Columbia blood Agar plates. In addition, a microbiological analysis of disinfectants, drugs used in dialysis unit and samples collected from the reverse osmosis water unit (ROW) and from the ROW delivery line were performed. None of the samples obtained from the ROW and from the ROW delivery line resulted positive. Thus, a microbiological analysis of the biofilm attached on the loading pipes (LP) and on the loading plastic tubes (LPT) that connect the hemodialyzer consoles (HC) to the ROW delivery line were performed. Briefly, LTP were subjected to ultrasound sonication at 30-40 KHz (BactoSonic-Bandelin), to disrupt the bacterial biofilm. The material obtained from sonication was cultured. Bacteria was identified by an automated mass spectrometry (MALDI-TOF VITEK®MS, Biomerieux). Bacteremia due to RB and BB was confirmed in 7 out of 39 (17.9%) of the hemodialyzed patients with a long-term indwelling CVC. 1 out of 7 was asymptomatic. Baseline characteristics of the 6 symptomatic patients were: mean age 68±16 years; mean C-reactive protein 4.48±1.3 mg/dl; mean procalcitonin 13.27±11.07 ng/ml; mean body temperature 37.9±1.4°C. The antibiotic therapy was decided according to antibiogram and included meropenem and ciprofloxacin. CVC were removed in all infected patients between 6 to 11 days from the diagnosis. Concomitantly, a new one was placed. None of the HD patients with arterio-venous fistulae developed bacteremia. RB and BB were isolated in the biofilm of 11 out of 37 LPT. Thus, we modified the ROW delivery line in order to set up a scheduled chemical and physical disinfections of the ROW delivery line with the hemodialysis consoles connected avoiding the risk of new contamination of the LPT and loading pipes. Briefly, on alternate months the whole system that include ROW delivery line (PE-Xa Medical Device, Fresenius Medical Care), loading pipes, LPT and hemodialysis consoles are disinfected by hot water (90°C) produced by a water heater (AquaB plus HF, Fresenius Medical Care) and by chemical disinfectant, 5% peracetic acid according to the protocols made by the console fabricant. In addition, we added to the reverse osmosis system a filtration module of 0.01 μm (AquaUF, Fresenius Medical Care) prior to the ROW delivery line, Figure 1. Awaiting for the modification of the ROW delivery line, the patients with CVC were dialyzed using a portable water treatment unit. After more than 14 months from the modification of the whole system for production and delivery of ROW none of the hemodialyzed patients developed infection by RB and BB. Our experience suggests that infection outbreak by unusual bacteria such as RB and BB could be successful treated using antibiotic therapy. Nevertheless, in dialysis unit the source of infection should be investigated in order to adopt the countermeasures necessary to reduce the risk of new infections. Hemodialysis water treatment system scheme.

9 July 2024 in Kidney and Dialysis
Verified
Journal Article
Open access
PDF file
MVMauro Valente
Mauro Valente
FOFRANCESCA ORECCHIONI
FRANCESCA ORECCHIONI
FBFabiana Brigante
Fabiana Brigante
MMMaria Ilaria Moretti
Maria Ilaria Moretti
RMRoberta Mariani
Roberta Mariani
ARAndrea Ranghino
Andrea Ranghino
The Ralstonia species (RB) and Burkholderia species (BB) are bacteria responsible for nosocomial infections in frail patients such as hemodialyzed (HD) patients. Here, we report how we managed an outbreak caused by RB and BB that occurred in a dialysis unit. From the 7th to the 16th of April 2021, an infection due to RB and BB occurred in 7 out of 39 (17.9%) HD patients with central venous catheter (CVC). Disinfectants, CVC-lock therapy solutions, water by reverse osmosis unit (ROW) and dialysis concentrates were cultured, including the biofilm from the loading plastic tubes (LPTs) that connect the hemodialysis consoles (HCs) to the ROW delivery line. The antibiotic treatment was successful for all patients. RB and BB were isolated in the biofilm of 11/37 LPTs. Three out of 11 positive LPTs were associated with the infected patients. The ROW delivery line was modified to provide a whole disinfection with the HCs connected, avoiding the risk of new contamination of the LPTs. A filtration module of 0.01 mm was added prior to the ROW delivery line. Our experience suggests that outbreaks sustained by unusual bacteria such as RB and BB should be promptly investigated to treat the infected patients with the appropriate therapy and to identify the possible source of infection, making the needful changes to achieve a safer dialysis unit.

9 November 2022 in Journal of Urology and Renal Diseases
Verified
Journal Article
Open access
PDF file
FBFabiana Brigante
Fabiana Brigante
RMRoberta Mazzucchelli
Roberta Mazzucchelli
VVValentina Viola
Valentina Viola
VRVittoria Rizzo
Vittoria Rizzo
GTGiada Tortora
Giada Tortora
ARAndrea Ranghino
Andrea Ranghino
Adenine Phosphoribosyltransferase (APRT) deficiency is a rare autosomal recessive disorder of the purine metabolism which results in the conversion of adenine into 2,8 Dihydroxyadenine (DHA) due to the activity of the xanthine Oxidoreductase (XOR). Patients affected by APRT deficiency if not treated with inhibitors of XOR may develop 2,8- DHA nephropathy that in turn might progress to End-Stage Kidney Disease (ESKD) with the need of kidney transplant. The high rate of misdiagnosis of 2,8-DHA nephropathy in native kidneys could lead to the failure of kidney graft in transplanted patients affected by APRT deficiency. Here, we report the case of a 61-years old patient with ESKD due to misdiagnosed 2,8-DHA nephropathy who underwent kidney transplantation and developed an early recurrence of 2,8-DHA nephropathy in the graft successfully treated with steroids, hydration, XOR-inhibitors and hemodiafiltration. In our knowledge this is the first time that a hemodiafiltration has be used in combination to steroids and XOR-inhibitors in the treatment of a 2,8- DHA nephropathy recurrence in kidney graft. Keywords: 2,8-DHA nephropathy; Adenine Phosphoribosyltransferase (APRT) deficiency; Case report; Hemodiafiltration; Kidney transplant List of Abbreviations: APRT: Adenine Phosphoribosyltransferase; CKD: Chronic Kidney Disease; CMV: Cytomegalovirus; DHA: Adenine Into 2,8 Dihydroxyadenine; DHAN: 2,8-DHA Nephropathy; ESKD: End-Stage Kidney Disease; HDF: Hemodiafiltration; MPA: Mycophenolic Acid; sCr: Serum Creatinine ; TCMR: T Cell-Mediated Rejection; XOR: Xanthine Oxidoreductase